Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q2 2025 value amounting to $37000.0.

  • Rani Therapeutics Holdings' Capital Expenditures fell 4218.75% to $37000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $119000.0, marking a year-over-year decrease of 7054.46%. This contributed to the annual value of $268000.0 for FY2024, which is 7819.37% down from last year.
  • Rani Therapeutics Holdings' Capital Expenditures amounted to $37000.0 in Q2 2025, which was down 4218.75% from $51000.0 recorded in Q1 2025.
  • Rani Therapeutics Holdings' Capital Expenditures' 5-year high stood at $530000.0 during Q4 2022, with a 5-year trough of $31000.0 in Q4 2024.
  • Over the past 5 years, Rani Therapeutics Holdings' median Capital Expenditures value was $151500.0 (recorded in 2021), while the average stood at $206111.1.
  • Per our database at Business Quant, Rani Therapeutics Holdings' Capital Expenditures surged by 83061.22% in 2022 and then plummeted by 8143.71% in 2024.
  • Rani Therapeutics Holdings' Capital Expenditures (Quarter) stood at $222000.0 in 2021, then soared by 138.74% to $530000.0 in 2022, then tumbled by 68.49% to $167000.0 in 2023, then crashed by 81.44% to $31000.0 in 2024, then rose by 19.35% to $37000.0 in 2025.
  • Its Capital Expenditures stands at $37000.0 for Q2 2025, versus $51000.0 for Q1 2025 and $31000.0 for Q4 2024.